Literature DB >> 12719568

Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS.

Amitinder Kaur1, Nadine Kassis, Corrina L Hale, Meredith Simon, Michelle Elliott, Alicia Gomez-Yafal, Jeffrey D Lifson, Ronald C Desrosiers, Fred Wang, Peter Barry, Michael Mach, R Paul Johnson.   

Abstract

Although opportunistic infections like cytomegalovirus (CMV) are common sequelae of end-stage AIDS, the immune events leading to CMV reactivation in human immunodeficiency virus (HIV)-infected individuals are not well defined. The role of cellular and humoral CMV-specific immune responses in immune control of latent CMV infection was evaluated prospectively in a cohort of 11 simian immunodeficiency virus (SIV)-infected CMV-seropositive rhesus macaques, 6 of whom had histologic evidence of CMV disease at death. Macaques with CMV disease differed from macaques without CMV disease in having significantly higher levels of plasma SIV RNA and CMV DNA and significantly lower titers of anti-CMV binding antibodies (Abs) at the time of death. A significant decline in anti-CMV Abs and CMV-specific CD4(+) and CD8(+) T lymphocytes over time was observed in the macaques with CMV disease, but not in the macaques without CMV disease. Reduction in CMV-specific CD8(+) T lymphocytes and anti-CMV neutralizing Abs was significantly correlated with a decline in CMV-specific CD4(+) T lymphocytes. Although declines in CMV-specific T lymphocytes alone were sufficient for reactivation of low-level CMV viremia, high-level viremia (>1,000 copies of CMV DNA per ml of plasma) was observed when anti-CMV neutralizing and binding Abs had also declined. Thus, the occurrence of CMV reactivation-associated disease in AIDS is associated with suppression of both cellular and humoral CMV-specific immune responses. The underlying mechanism may be a dysfunction of memory B and CD8(+) T lymphocytes associated with SIV-induced impairment of CMV-specific CD4(+) T-cell help.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719568      PMCID: PMC154043          DOI: 10.1128/jvi.77.10.5749-5758.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients.

Authors:  K Schoppel; C Schmidt; H Einsele; H Hebart; M Mach
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

2.  Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1.

Authors:  K V Komanduri; M N Viswanathan; E D Wieder; D K Schmidt; B M Bredt; M A Jacobson; J M McCune
Journal:  Nat Med       Date:  1998-08       Impact factor: 53.440

3.  Humoral immunity due to long-lived plasma cells.

Authors:  M K Slifka; R Antia; J K Whitmire; R Ahmed
Journal:  Immunity       Date:  1998-03       Impact factor: 31.745

4.  Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center.

Authors:  R D Schrier; C A Wiley; C Spina; J A McCutchan; I Grant
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling.

Authors:  S Jacquot; T Kobata; S Iwata; C Morimoto; S F Schlossman
Journal:  J Immunol       Date:  1997-09-15       Impact factor: 5.422

6.  An animal model for acute and persistent Epstein-Barr virus infection.

Authors:  A Moghaddam; M Rosenzweig; D Lee-Parritz; B Annis; R P Johnson; F Wang
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

7.  A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus.

Authors:  R C Desrosiers; V G Sasseville; S C Czajak; X Zhang; K G Mansfield; A Kaur; R P Johnson; A A Lackner; J U Jung
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

8.  Nucleotide sequence and molecular analysis of the rhesus cytomegalovirus immediate-early gene and the UL121-117 open reading frames.

Authors:  P A Barry; D J Alcendor; M D Power; H Kerr; P A Luciw
Journal:  Virology       Date:  1996-01-01       Impact factor: 3.616

9.  Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection.

Authors:  B Polić; H Hengel; A Krmpotić; J Trgovcich; I Pavić; P Luccaronin; S Jonjić; U H Koszinowski
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307

Review 10.  The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses.

Authors:  S A Kalams; B D Walker
Journal:  J Exp Med       Date:  1998-12-21       Impact factor: 14.307

View more
  30 in total

1.  Rhesus cytomegalovirus encodes seventeen microRNAs that are differentially expressed in vitro and in vivo.

Authors:  Meaghan H Hancock; Rebecca S Tirabassi; Jay A Nelson
Journal:  Virology       Date:  2012-02-02       Impact factor: 3.616

2.  Genomic sequence of rhesus cytomegalovirus 180.92: insights into the coding potential of rhesus cytomegalovirus.

Authors:  Pierre Rivailler; Amitinder Kaur; R Paul Johnson; Fred Wang
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Expanded tissue targets for foamy virus replication with simian immunodeficiency virus-induced immunosuppression.

Authors:  S M Murray; L J Picker; M K Axthelm; M L Linial
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  The infectious diseases consequences of monkey business.

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-01       Impact factor: 2.471

5.  Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation.

Authors:  Se Hyun Choi; Chang Ho Yoon; Hyun Ju Lee; Hong Pyo Kim; Jong Min Kim; Jeong-Hwan Che; Kyoung Min Roh; Hyuk Jin Choi; Jiyeon Kim; Eung Soo Hwang; Chung-Gyu Park; Mee Kum Kim
Journal:  Xenotransplantation       Date:  2018-07       Impact factor: 3.907

6.  Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications.

Authors:  Helen L Wu; Whitney C Weber; Christine Shriver-Munsch; Tonya Swanson; Mina Northrup; Heidi Price; Kimberly Armantrout; Mitchell Robertson-LeVay; Jason S Reed; Katherine B Bateman; Eisa Mahyari; Archana Thomas; Stephanie L Junell; Theodore R Hobbs; Lauren D Martin; Rhonda MacAllister; Benjamin N Bimber; Mark K Slifka; Alfred W Legasse; Cassandra Moats; Michael K Axthelm; Jeremy Smedley; Anne D Lewis; Lois Colgin; Gabrielle Meyers; Richard T Maziarz; Benjamin J Burwitz; Jeffrey J Stanton; Jonah B Sacha
Journal:  Xenotransplantation       Date:  2020-01-13       Impact factor: 3.907

7.  Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques.

Authors:  L E Pereira; F Villinger; H Wulff; A Sankaranarayanan; G Raman; A A Ansari
Journal:  Exp Biol Med (Maywood)       Date:  2007-11

8.  Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication.

Authors:  Thaidra Gaufin; Ruy M Ribeiro; Rajeev Gautam; Jason Dufour; Daniel Mandell; Cristian Apetrei; Ivona Pandrea
Journal:  Retrovirology       Date:  2010-05-11       Impact factor: 4.602

9.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.

Authors:  Kristina Abel; Lisa Strelow; Yujuan Yue; Meghan K Eberhardt; Kimberli A Schmidt; Peter A Barry
Journal:  Vaccine       Date:  2008-08-27       Impact factor: 3.641

10.  The Knife's Edge of Tolerance: Inducing Stable Multilineage Mixed Chimerism but With a Significant Risk of CMV Reactivation and Disease in Rhesus Macaques.

Authors:  H B Zheng; B Watkins; V Tkachev; S Yu; D Tran; S Furlan; K Zeleski; K Singh; K Hamby; C Hotchkiss; J Lane; S Gumber; A B Adams; L Cendales; A D Kirk; A Kaur; B R Blazar; C P Larsen; L S Kean
Journal:  Am J Transplant       Date:  2016-09-19       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.